Cytokinetics to Present at Upcoming Healthcare Conferences
(Thomson Reuters ONE) -
South San Francisco, CA, February 22, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that members of its management team are scheduled to
participate at the following healthcare conferences:
Canaccord Genuity Orphan Drug One-on-One Day
Date: Monday, February 25(th)
Location: Omni Berkshire Place, New York, NY
Not webcast: one-on-one meetings only
Attendees: Sharon Barbari, Executive Vice President, Finance & Chief Financial
Officer; Fady Malik, MD, PhD, FACC, Senior Vice President, Research and Early
Development
Cowen & Company 33(rd) Annual Health Care Conference
Date: Monday, March 4(th)
Time: 1:30 PM Eastern Time
Location: Boston Marriott Copley Place Hotel, Boston, Massachusetts
Presenter: Robert I. Blum, President and Chief Executive Officer
Interested parties may access the live webcast of the Cowen & Company
presentation by visiting the Investor Relations section of the Cytokinetics
website at www.cytokinetics.com. The webcast replay of the presentation will be
archived on the Presentations page within the Investor Relations section of
Cytokinetics' website for two weeks following the completion of the event.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize omecamtiv
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization participation rights. Cytokinetics is independently
developing tirasemtiv, a skeletal muscle activator, as a potential treatment for
diseases and conditions associated with aging, muscle wasting or neuromuscular
dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials
program and has been granted orphan drug designation and fast track status by
the U.S. Food and Drug Administration and orphan medicinal product designation
by the European Medicines Agency for the potential treatment of amyotrophic
lateral sclerosis, a debilitating disease of neuromuscular impairment in which
treatment with tirasemtiv produced potentially clinically relevant
pharmacodynamic effects in Phase II trials. All of these drug candidates have
arisen from Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell. Additional
information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but not
limited to, potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical development or
product approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug candidates may
have unexpected adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the Securities and
Exchange Commission.
Contacts:
Cytokinetics, Incorporated:
Joanna (Jodi) L. Goldstein
Manager, Corporate Communications and Marketing
(650) 624-3000
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cytokinetics, Inc. via Thomson Reuters ONE
[HUG#1680561]
Unternehmensinformation / Kurzprofil:
Datum: 22.02.2013 - 22:00 Uhr
Sprache: Deutsch
News-ID 232485
Anzahl Zeichen: 5577
contact information:
Town:
SOUTH SAN FRANCISCO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 144 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytokinetics to Present at Upcoming Healthcare Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytokinetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
